No Data
CSPC Innovation Pharma Grants US Firm Right to Cancer Drug
CSPC Innovation Pharmaceutical (300765.SZ) subsidiary signs exclusive collaboration agreement with Radiance Biopharma for SYS6005.
CSPC Innovation Pharmaceutical (300765.SZ) announced that its holding subsidiary CSPC PHARMA Giant Stone Biopharmaceutical Co., Ltd. (...)
Estimating The Fair Value Of CSPC Innovation Pharmaceutical Co., Ltd. (SZSE:300765)
CSPC Innovation Pharmaceutical's Unit Gets NMPA's Nod for Asthma Drug
CSPC Innovation Pharmaceutical (300765.SZ) has received a cumulative Shareholding of 1.7152 million shares from its controlling Shareholder, Enbipu Pharmaceuticals.
CSPC Innovation Pharmaceutical (300765.SZ) announced that the implementation period of the shareholding plan by its controlling shareholder Enbiopu Pharmaceutical has exceeded half the time, and...
CSPC Innovation Pharmaceutical (300765.SZ): The holding subsidiary has obtained the pharmaceutical registration certificate for a new indication of injectable omalizumab.
On February 10, Gelonghui reported that CSPC Innovation Pharmaceutical (300765.SZ) announced that its subsidiary CSPC PHARMA JuShi Biotechnology Co., Ltd. (referred to as "JuShi Biotechnology") recently received notification from the National Medical Products Administration, approving the use of Omilizumab injection (commodity name: Enyitan) for the treatment of moderate to severe persistent allergic asthma. This marks the second indication approved for Enyitan in China. Enyitan is a humanized monoclonal antibody targeting immunoglobulin E (IgE) developed by the group, and is a biosimilar to Zebulon. The newly approved indication is for moderate to severe persistent allergic asthma.